Advertisement

Info Diabetologie

, Volume 12, Issue 6, pp 33–38 | Cite as

Sensomotorische Diabetische Polyneuropathie

Neuropathie bei Diabetes oft unerkannt — und auch im ZNS

  • Ovidiu Alin StirbanEmail author
zertifizierte fortbildung
  • 157 Downloads

Zusammenfassung

Die diabetische sensomotorische Polyneuropathie (DSPN) ist eine der häufigsten Komplikationen des Diabetes mellitus. Die Pathogenese wird immer besser verstanden. Die Beteiligung des zentralen Nervensystems (ZNS) ist eine relativ neue Erkenntnis — mit Konsequenzen für die Therapie. Obwohl das Screening und die Diagnosestellung relativ einfach und kostengünstig sind, gibt es noch eine hohe Dunkelziffer betroffener Patienten.

Literatur

  1. 1.
    Pop-Busui R et al.. Diabetic Neuropathy: A Position Statement by the American Diabetes Association. Diabetes Care. 2017;40:136–54.CrossRefGoogle Scholar
  2. 2.
    Boulton AJ et al.. Diabetic somatic neuropathies. Diabetes Care. 2004;27:1458–86CrossRefGoogle Scholar
  3. 3.
    Eaton SE et al.. Spinal-cord involvement in diabetic peripheral neuropathy. Lancet. 2001;358:35–36.CrossRefGoogle Scholar
  4. 4.
    Selvarajah D et al.. Magnetic resonance neuroimaging study of brain structural differences in diabetic peripheral neuropathy. Diabetes Care. 2014;37:1681–8.CrossRefGoogle Scholar
  5. 5.
    Li J et al.. Functional magnetic resonance imaging reveals differences in brain activation in response to thermal stimuli in diabetic patients with and without diabetic peripheral neuropathy. PLOS ONE. 2018. https://doi.org/10.1371/journal.pone.0190699Google Scholar
  6. 6.
    Nationale Versorgungs-Leitlinie Neuropathie bei Diabetes im Erwachsenenalter, Kurzfassung Auflage, 2012 Version 3.Google Scholar
  7. 7.
    Pop-Busui R et al.. Cardiovascular Autonomic Neuropathy and Cardiovascular Outcomes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. Diabetes Care. 2017;40:94–100.CrossRefGoogle Scholar
  8. 8.
    Gaede P et al.. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580–91.CrossRefGoogle Scholar
  9. 9.
    Smith AG et al.. Lifestyle intervention for pre-diabetic neuropathy. Diabetes Care. 2006;29:1294–9.CrossRefGoogle Scholar
  10. 10.
    Mehra S et al.. Corneal confocal microscopy detects early nerve regeneration after pancreas transplantation in patients with type 1 diabetes. Diabetes Care. 2007;30:2608–12.CrossRefGoogle Scholar
  11. 11.
    Look AHEAD Research group. Effects of a long-term lifestyle modification programme on peripheral neuropathy in overweight or obese adults with type 2 diabetes: the Look AHEAD study. Diabetologia. 2017;60:980–8.CrossRefGoogle Scholar
  12. 12.
    Ziegler D et al.. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabetic Medicine. 2004;21:114–21.CrossRefGoogle Scholar
  13. 13.
    Ziegler D et al.. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care. 2006;29:2365–70.CrossRefGoogle Scholar
  14. 14.
    Ziegler D et al.. Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care. 2011; 34: 2054–60.CrossRefGoogle Scholar
  15. 15.
    Rudroju N et al.. Comparative efficacy and safety of six antidepressants and anticonvulsants in painful diabetic neuropathy: a network meta-analysis. Pain Physician. 2013;16:E705–14PubMedGoogle Scholar
  16. 16.
    Vinik AI et al.. Capsaicin 8% patch repeat treatment plus standard of care (SOC) versus SOC alone in painful diabetic peripheral neuropathy: a randomised, 52-week, open-label, safety study. BMC Neurology. 2016;16:251.CrossRefGoogle Scholar
  17. 17.
    Reichstein L et al.. Effective treatment of symptomatic diabetic polyneuropathy by high-frequency external muscle stimulation. Diabetologia. 2005;48:824–8.CrossRefGoogle Scholar
  18. 18.
    Stracke H et al.. Benfotiamine in diabetic polyneuropathy (BENDIP): results of a randomised, double blind, placebo-controlled clinical study. Exp. Clin. Endocrinol. Diab. 2008; 116:600–5.CrossRefGoogle Scholar
  19. 19.
    Stirban OA et al.. Benfotiamine in the treatment of sensorimotor diabetic polyneuropathy. Abstract book. Neurodiab, Bucharest, 2016.Google Scholar
  20. 20.
    Bongaerts BW et al.. Older subjects with diabetes and prediabetes are frequently unaware of having distal sensorimotor polyneuropathy: the KORA F4 study. Diabetes Care. 2013;36:1141–6.CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018

Authors and Affiliations

  1. 1.Schön Klinik Nürnberg FürthFürthDeutschland

Personalised recommendations